These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16300168)

  • 41. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.
    Neuvonen PJ; Jalava KM
    Clin Pharmacol Ther; 1996 Jul; 60(1):54-61. PubMed ID: 8689812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
    Dieterle W; Corynen S; Mann J
    Br J Clin Pharmacol; 2004 Oct; 58(4):433-6. PubMed ID: 15373937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioequivalence of two tablet formulations of atenolol after single oral administration in healthy volunteers.
    Niopas I; Daftsios AC; Xanthakis I; Nikolaidis N; Njau SN
    Arzneimittelforschung; 2000 Mar; 50(3):243-7. PubMed ID: 10758775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):305-14. PubMed ID: 18327992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aliskiren: clinical experience and future perspectives of renin inhibition.
    Sureshkumar KK; Vasudevan S; Marcus RJ; Hussain SM; McGill RL
    Expert Opin Pharmacother; 2008 Apr; 9(5):825-37. PubMed ID: 18345958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
    Oh BH; Mitchell J; Herron JR; Chung J; Khan M; Keefe DL
    J Am Coll Cardiol; 2007 Mar; 49(11):1157-63. PubMed ID: 17367658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
    Swamy MV; Cooma I; Reddy BS; Rao CV
    Int J Oncol; 2002 Apr; 20(4):753-9. PubMed ID: 11894121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bioequivalence study of generic atenolol tablets in healthy Thai volunteers.
    Rojanasthien N; Manorot M; Kumsorn B
    J Med Assoc Thai; 1999 Sep; 82(9):907-14. PubMed ID: 10561948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
    Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
    J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers.
    Mignini F; Tomassoni D; Streccioni V; Traini E; Amenta F
    Clin Exp Hypertens; 2008 Feb; 30(2):95-108. PubMed ID: 18293165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
    Brenner SS; Herrlinger C; Dilger K; Mürdter TE; Hofmann U; Marx C; Klotz U
    Clin Pharmacokinet; 2003; 42(3):283-92. PubMed ID: 12603175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aliskiren: renin inhibitor for hypertension management.
    Cheng JW
    Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.